8-(3-(<i>R</i>)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 DiabetesMatthias Eckhardt, Frank Himmelsbach, Holger Fuchs et al.|Journal of Medicinal Chemistry|2007Cited by 285
Time for a Fully Integrated Nonclinical–Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry PerspectiveHugo M. Vargas, Jean‐Pierre Valentin, Michael G. Rolf et al.|Clinical Pharmacology & Therapeutics|2020Cited by 96
3,5-Dihydro-imidazo[4,5-d]pyridazin-4-ones: A class of potent DPP-4 inhibitorsMatthias Eckhardt, Ralf Lotz, Norbert Hauel et al.|Bioorganic & Medicinal Chemistry Letters|2008Cited by 40
ChemInform Abstract: 3,5‐Dihydro‐imidazo[4,5‐d]pyridazin‐4‐ones: A Class of Potent DPP‐4 Inhibitors.Matthias Eckhardt, Ralf Lotz, Norbert Hauel et al.|ChemInform|2008Cited by 0
8-(3-(<em>R</em>)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetesMatthias Eckhardt, Frank Himmelsbach, Elke Langkopf et al.|DORA PSI (Paul Scherrer Institute)|2007Cited by 0